title: Role of peptido-leukotrienes in the genesis of early ventricular arrhythmias during acute myocardial ischaemia in rats.
abstract: Changes in cardiac ventricular concentrations of peptidoleukotrienes (peptido-LTs) following coronary artery ligation and the effects of lipoxygenase inhibition and leukotriene antagonism on the cardiovascular responses to acute myocardial ischaemia were studied in pentobarbitone-anaesthetised rats. It was found that the left ventricular peptido-LT levels significantly increased at 2.5 and 5 min after left coronary artery ligation while the changes in right ventricle were not statistically significant. Pretreatment with nordihydroguaiaretic acid 25, 50 or 100 mg/kg caused marked depletion of ventricular peptido-LT content, but did not significantly prevent the blood pressure or heart rate changes, the occurrence of ventricular tachycardia or fibrillation, or the mortality of the animals following coronary artery ligation. Administration of SK&F 102922, even at doses which caused marked decreases in blood pressure and heart rate, also did not significantly alter the cardiovascular changes and the mortality rate induced by left coronary artery ligation. It is, therefore, suggested that the occurrence of ventricular arrhythmias and haemodynamic changes during the early phase of acute myocardial ischaemia may not be due to the augmented synthesis of peptido-LTs in cardiac tissue.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Hong Kong.
authors.forename: A C
authors.initials: AC
authors.lastname: Chang
authors.forename: S
authors.initials: S
authors.lastname: Dai
authors.forename: C W
authors.initials: CW
authors.lastname: Ogle
authors.forename: W M
authors.initials: WM
authors.lastname: Tom
mesh_terms: D000208:Acute Disease; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000503:physiopathology; D001158:Arteries; D002319:Cardiovascular System / Q000503:physiopathology*; D003327:Coronary Disease / Q000150:complications*; D003331:Coronary Vessels; D003998:Dicarboxylic Acids / Q000494:pharmacology; D006352:Heart Ventricles / Q000378:metabolism; D020024:Leukotriene Antagonists; D015289:Leukotrienes / Q000502:physiology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D010455:Peptides / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
chemical_list: D003998:Dicarboxylic Acids; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D010455:Peptides; D009637:Masoprocol; C046472:5-(2-(8-phenyloctyl)phenyl)-4,6-dithianonanedioic acid